Skip NavigationSkip to Content

Comparative Analysis of Monkeypox Virus Infection of Cynomolgus Macaques by the Intravenous or Intrabronchial Inoculation Route

  1. Author:
    Johnson, R. F.
    Dyall, J.
    Ragl, D. R.
    Huzella, L.
    Byrum, R.
    Jett, C.
    St Claire, M.
    Smith, A. L.
    Paragas, J.
    Blaney, J. E.
    Jahrling, P. B.
  2. Author Address

    [Johnson, Reed F.] NIAID, Emerging Viral Pathogens Sect, EVPS, NIH, Bethesda, MD 20892 USA. [Dyall, Julie; Ragland, Dan R.; Huzella, Louis; Byrum, Russell; Jett, Catherine; St Claire, Marisa; Paragas, Jason; Jahrling, Peter B.] NIAID, Integrated Res Facil, NIH, Frederick, MD 21702 USA.;Johnson, RF, NIAID, Emerging Viral Pathogens Sect, EVPS, NIH, Bldg 33,Rm 2E19A,33 N Dr, Bethesda, MD 20892 USA.;johnsonreed@mail.nih.gov
    1. Year: 2011
    2. Date: Mar
  1. Journal: Journal of Virology
    1. 85
    2. 5
    3. Pages: 2112-2125
  2. Type of Article: Article
  3. ISSN: 0022-538X
  1. Abstract:

    Monkeypox virus (MPXV) infection has recently expanded in geographic distribution and can be fatal in up to 10% of cases. The intravenous (i.v.) inoculation of nonhuman primates (NHPs) results in an accelerated fulminant disease course compared to that of naturally occurring MPXV infection in humans. Alternative routes of inoculation are being investigated to define an NHP model of infection that more closely resembles natural disease progression. Our goal was to determine if the intrabronchial (i.b.) exposure of NHPs to MPXV results in a systemic disease that better resembles the progression of human MPXV infection. Here, we compared the disease course following an i.v. or i.b. inoculation of NHPs with 10-fold serial doses of MPXV Zaire. Classical pox-like disease was observed in NHPs administered a high virus dose by either route. Several key events were delayed in the highest doses tested of the i.b. model compared to the timing of the i.v. model, including the onset of fever, lesion appearance, peak viremia, viral shedding in nasal and oral swabs, peak cytokine levels, and time to reach endpoint criteria. Virus distribution across 19 tissues was largely unaffected by the inoculation route at the highest doses tested. The NHPs inoculated by the i.b. route developed a viral pneumonia that likely exacerbated disease progression. Based on the observations of the delayed onset of clinical and virological parameters and endpoint criteria that may more closely resemble those of human MPXV infection, the i.b. MPXV model should be considered for the further investigation of viral pathogenesis and countermeasures.

    See More

External Sources

  1. DOI: 10.1128/jvi.01931-10
  2. WOS: 000286974900018

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel